Breast cancer is the most common form of cancer among women in the United States and is second only to lung cancer as the cause of cancer-related death; in 2007, more than 200,000 new cases of breast cancer were diagnosed and approximately 40,000 women died. The five-year survival rate for breast cancer is about 95% if the cancer has not spread at the time of diagnosis; hence early diagnostics is vital. One of the important challenges is blood-based, low cost detection of breast cancers, especially for very young women wherein mammography is not reliable. Actually, availability of low cost, blood based breast cancer detection will drastically increase efficiency of detection of BC for women of all ages. Ten- to twenty-fold lower cost of blood-based modalities will be a strong selling point in comparison to current imaging modalities. This project focuses on increase of statistics of cohort on which the validation of our method was performed. We expect to reach the 98% sensitivity and 96% specificity.
Public Health Relevance: Breast cancer is the most common form of cancer among women in the United States. The five-year survival rate for breast cancer is about 95% if the cancer has not spread at the time of diagnosis; hence early diagnostics is vital. Important challenge is detection of breast cancers in younger women, because they often occur at a relatively young age and are difficult to detect by both mammography and MRI. However, because of relatively low prevalence, the method with sensitivity/specificity of about 98% needs to be developed. We propose the additional validation of our blood-based tests, which already achieved the 95% sensitivity/specificity.
Public Health Relevance Statement: Narrative Breast cancer is the most common form of cancer among women in the United States. The five-year survival rate for breast cancer is about 95% if the cancer has not spread at the time of diagnosis; hence early diagnostics is vital. Important challenge is detection of breast cancers in younger women, because they often occur at a relatively young age and are difficult to detect by both mammography and MRI. However, because of relatively low prevalence, the method with sensitivity/specificity of about 98% needs to be developed. We propose the additional validation of our blood-based tests, which already achieved the 95% sensitivity/specificity.
Project Terms: Age; Age-Years; Artifacts; Benign Prostatic Hypertrophy; Berlin; Bio-Informatics; Bioinformatics; Blood; Blood Serum; Breast Cancer Detection; Breast cancer screening; Buffaloes; Cancer Cause; Cancer Detection; Cancer Etiology; Cancer Hospital; Cancer of Breast; Cancer of Lung; Cancer of Prostate; Cancer of the Ovary; Cancers; Cessation of life; City of Berlin; Collaborations; DCTD; Data; Data Set; Dataset; Death; Dependence; Detection; Diagnosis; Diagnostic; Diagnostic tests; Division of Cancer Treatment and Diagnosis; Division of Cancer Treatment, Diagnosis and Center; Evaluation; France Paris; Germany; HOSP; Hospitals; Institutes; Low Prevalence; MMG; MR Imaging; MR Tomography; MRI; Magnetic Resonance Imaging; Magnetic Resonance Imaging Scan; Malignant Melanoma; Malignant Neoplasms; Malignant Ovarian Neoplasm; Malignant Ovarian Tumor; Malignant Pancreatic Neoplasm; Malignant Tumor; Malignant Tumor of the Breast; Malignant Tumor of the Lung; Malignant Tumor of the Ovary; Malignant Tumor of the Prostate; Malignant neoplasm of breast; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Malignant prostatic tumor; Mammogram; Mammography; Measurement; Measures; Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance; Method LOINC Axis 6; Methodology; Methods; Modality; Morphologic artifacts; NIH; NMR Imaging; NMR Tomography; National Institutes of Health; National Institutes of Health (U.S.); Nuclear Magnetic Resonance Imaging; Pancreas Cancer; Pancreatic Cancer; Paris; Paris, France; Pennsylvania; Performance; Prostate CA; Prostate Cancer; Prostatic Cancer; Prostatic Hyperplasia, Benign; Prostatic Hypertrophy, Benign; Proteins; Proteomics; Pulmonary Cancer; Pulmonary malignant Neoplasm; Reporting; Reticuloendothelial System, Blood; SBIR; SBIRS (R43/44); Sampling; Science of Statistics; Sensitivity and Specificity; Serum; Small Business Innovation Research; Small Business Innovation Research Grant; Specificity; Statistics; Survival Rate; Testing; Time; Uncertainty; United States; United States National Institutes of Health; Universities; Validation; Woman; Work; Zeugmatography; base; benign prostate hyperplasia; biomarker; c new; cancer diagnosis; cohort; cost; doubt; gene product; imaging modality; improved; innovate; innovation; innovative; lung cancer; malignancy; malignant breast neoplasm; mammary cancer detection; melanoma; neoplasm/cancer; novel; ovarian cancer; public health relevance; statistics; ward
